Trends in first-year utilization costs of HIV medications

American Journal of Pharmacy Benefits

Volumn 4, Issue 5, 2012, Pages 228-234

  Palmieri, Anthony ^a   Mostovoy, Lisa ^a   Akinbosoye, Osayi ^a   Szychowski, John A ^a   Sehman, Marina L ^a   Matlin, Olga S ^a  

^a CVS Caremark   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATAZANAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; LOPINAVIR PLUS RITONAVIR; RALTEGRAVIR; RITONAVIR;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DRUG APPROVAL; DRUG COST; DRUG SAFETY; DRUG UTILIZATION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION CONTROL; INFECTION PREVENTION; MALE; PATIENT ASSESSMENT; TREATMENT INDICATION; TREATMENT PLANNING; TREND STUDY;

EID: 84867842218     PISSN: 19454481     EISSN: 21642494     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Centers for Disease Control and Prevention (CDC). Results of the Expanded HIV Testing Initiative-25 jurisdictions, United States, 2007-2010. MMWR Morb Mortal Wkly Rep. 2011;60(24):805-810.
2. Centers for Disease Control and Prevention. National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. HIV in the United States: at a glance, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. http://www.cdc.gov/hiv/resources/factsheets/us.htm. Published March 2012. Accessed July 22, 2012. Publication CS231128.
3. American Public Health Association. Adherence to HIV treatment regimens: rec-ommendations for best practices. http://www.apha.org/NR/rdonlyres/1F7F3BD1-BE3D-440E-B2F4-16E5EC6C4DBE/0/Best_Practices_new.pdf. Published June 2004. Accessed July 10, 2012.
4. Panel on Antiretroviral Guidelines for Adults and Adolescents. Department of Health and Human Services. AIDSinfo. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://aidsinfo.nih.gov/con-tentfiles/lvguidelines/AdultandAdolescentGL.pdf. Published March 27, 2012. Accessed June 25, 2012.
5. Bookstaver PB. HIV infection and AIDS. In: American College of Clinical Phar-macy. PSAP. 7th ed. Lenexa, KS: American College of Clinical Pharmacy; 2012:7-25.
6. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm312210.htm. Published July 16, 2012. Accessed July 22, 2012.
7. Sutter S. FDA approves truvada for PrEP with bolstered labeling but no restricted distribution. The Pink Sheet Daily. Published July 16, 2012.
8. Gilead Sciences, Inc. US Food and Drug Administration approves Gilead's Truvada for reducing the risk of acquiring HIV. http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&id=1715013. Published July 16, 2012. Accessed July 17, 2012.
9. Marcus A, McKay B. Fight over use of HIV drugs. The Wall Street Journal. Published March 7, 2012.
10. Centers for Disease Control and Prevention. HIV cost-effectiveness. http://www.cdc.gov/hiv/topics/preventionprograms/ce/index.htm. Published 5, 2012. Accessed July 12, 2012.
11. Aggleton P, Wood K, Malcolm A, Parker R; UNAIDS. HIV-related stigma, dis-crimination and human rights violations: case studies of successful programmes. UNAIDS Best Practice Collection. http://data.unaids.org/publications/irc-pub06/jc999-humrightsviol_en.pdf. Published 2005. Accessed July 16, 2012.
12. McNeil DG, Rapid H.I.V. home test wins federal approval. The New York Times. Published July 3, 2012.
13. OraSure Technologies, Inc. The OraQuick ADVANCE rapid HIV-1/2 antibody test detects antibodies to HIV-1 and HIV-2 in 20 minutes. http://www.orasure.com/products-infectious/products-infectious-oraquick.asp. Published May 7, 2009. Accessed July 22, 2012.
14. Judy Stone. Over-the-counter OraQuick HIV test: what does this mean for you? Scientific American Blog. http://blogs.scientificamerican.com/molecules-to-medicine/2012/07/09/over-the-counter-oraquick-hiv-test-what-does-this-mean-for-you/. Published July 9, 2012. Accessed July 21, 2012.
15. OraSure Technologies, Inc. Final Advisory Committee Briefing Materials: Available for Public Release: Blood Products Advisory Committee Briefing Docu-ment. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeeting-Materials/BloodVaccinesandOtherBiologics/BloodProductsAdvisoryCommittee/UCM303652.pdf. Published May 15, 2012. Accessed July 22, 2012.
16. OraQuick Advance Rapid HIV-1/2 Antibody Test Package Insert. http://www.orasure.com. Accessed July 21, 2012.
17. Parloff R. The quiet scandal of the HIV home test kit. http://features.blogs.fortune.cnn.com/2012/07/09/oraquick-hiv-test/. Published July 9, 2012. Ac-cessed July 22, 2012.
18. OraQuick HIV Test. http://oraquickhivtests.com/. Published 2011. Accessed July 23, 2012.
19. Soper S. FDA approves OraSure at-home HIV test. The Morning Call. http://articles.mcall.com/2012-07-03/business/mc-oraquick-hiv-test-ap-proved-20120703_1_orasure-ceo-douglas-michels-oraquick-in-home-hiv-test-orasure-technologies. Published July 3, 2012. Accessed July 31, 2012.
20. Sutter S, Gilead's quad makes it through FDA panel review despite renal safety concerns. The Pink Sheet. 2012;74(20).
21. CVS Caremark Specialty Product Evaluation Worksheet. June 2012.
22. Hayes E. Gilead files once-daily integrase inhibitor Elvitegravir with FDA. The Pink Sheet Daily. June 28, 2012.
23. Walker EP. Home HIV Test Wins FDA Nod. MedPage Today. http://www.medpagetoday.com/HIVAIDS/HIVAIDS/33610. Published July 3, 2012. Accessed July 22, 2012.